Cytodyn Inc (CYDY)

[stockorus]

Looking more carefully at page 17, the last chart comparing Rantes for LL and placebo,

the distribution for both seem mostly clustered near each other, the mean or median being slightly less for placebo than for LL. I doubt we can say placebo patients had significantly less Rantes in the system than LL. Both groups had slightly decreased Rantes overall at week 4 compared to baseline, with placebo for whatever reason reducing a bit more.

My logic however for LL was that since it blocks CCR5 in lungs etc., the organs should not attract CCL5 in the LL patients as much as it would in placebo patients, and therefore we should find a significantly greater % reduction of CCL5 in LL patients than in placebo patients. This clearly is not the case.

The conclusion from this may only be that Rantes may not be the key problem for LH patients unlike for the critical covid patients. The MOA of LL (if it works for LH) for LH patients is not about its blocking of ccr5 or reducing the presence of ccl5. Likely something else.

Pg 16 shows biomarkers for which LL seems to have higher and positive % change than the placebo. These may be more relevant for LH than change in ccl5.

???